PTO/SB/08a (05-07)
Approved for use through 11/30/2007 OMB 0651-0031
U S Patent and Trademark Office, U S OEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number	10575119
Filing Date	2006-05-16
First Named Inventor	Charles Cantor
Art Unit	1634
Examiner Name	Misook YU
Attorney Docket Number	701586-054202

U.S.PATENTS Remove

Examiner Initial*	Cite No	Patent Number	Kind Code[1]	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1					

If you wish to add additional U.S. Patent citation information please click the Add button. Add

U.S.PATENT APPLICATION PUBLICATIONS Remove

Examiner Initial*	Cite No	Publication Number	Kind Code[1]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1	20040081993	A1	2004-04-29	Cantor	(related application)
	2	20040224331	A1	2004-11-11	Cantor	(related application)
	3	20070122805	A1	2007-05-31	Cantor	(related application)
	4	20070207466	A1	2007-09-06	Cantor	(related application)
	5	20020025532		2002-02-28	Huang	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10575119
	Filing Date	2006-05-16
	First Named Inventor	Charles Cantor
	Art Unit	1634
	Examiner Name	Misook YU
	Attorney Docket Number	701586-054202

	6	20030017487		2003-01-23	Xue	

If you wish to add additional U.S. Published Application citation information please click the Add button. Add

FOREIGN PATENT DOCUMENTS Remove

Examiner Initial*	Cite No	Foreign Document Number[3]	Country Code[2] i	Kind Code[4]	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	T[5]
	1	00/50869	WO	A2	2000-08-31	Incyte Pharmaceuticals Inc.		☐
	2	01/42496	WO	A2	2001-06-14	Pyrosequencing AB, et al.		☐
	3	01/68913	WO		2001-09-20	Genset		☐
	4	01/90399	WO	A2	2001-11-29	Dade Behring Inc.		☐
	5	01/96607	WO	A2	2001-12-20	Trustees of Boston University		☐

If you wish to add additional Foreign Patent Document citation information please click the Add button Add

NON-PATENT LITERATURE DOCUMENTS Remove

Examiner Initials*	Cite No	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.	T[5]
	1	AHMED et al., "Prenatal diagnosis of beta-thalassaemia in Pakistan: experience in a Muslim country" Prenatal Diagn 20(5):378-383, 2000.	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10575119
	Filing Date	2006-05-16
	First Named Inventor	Charles Cantor
	Art Unit	1634
	Examiner Name	Misook YU
	Attorney Docket Number	701586-054202

	2	AMICUCCI, P. et al., "Prenatal diagnosis of myotonic dystrophy using fetal DNA obtained from maternal plasma." Clinical Chemistry 46(2):301-302, 2000.	☐
	3	BÖCKER, "SNP and mutation discover using base-specific cleavage and MALDI-TOF mass spectrometry." Bioinformatics 19(Suppl 1):i44-i53, 2003.	☐
	4	BRAUN et al., "Improved Analysis of Microsatellites Using Mass Spectrometry." Genomics 46:18-23, 1997.	☐
	5	CHEUNG, M. C. et al., "Prenatal diagnosis of sickle cell anaemia and thalassaemia by analysis of fetal cells in maternal blood." Nat Genet 14:264-268, 1996	☐
	6	CHIU, R. W. K. and LO, Y. M. D., "Application of fetal DNA in maternal plasma for noninvasive prenatal diagnosis." Expert Rev Mol Diagn 2:32-40, 2002.	☐
	7	CHIU, R. W. K. et al., "Noninvasive prenatal exclusion of congenital adrenal hyperplasia by maternal plasma analysis: a feasibility study." Clin Chem 48:778-780, 2002.	☐
	8	CHIU, R. W. K. et al., "Prenatal exclusion of beta thalassaemia major by examination of maternal plasma." The Lancet 360:998-1000, 2002.	☐
	9	CLARK, A. G. et al., "Inference of haplotypes from PCR-amplified samples of diploid populations." Mol Biol Evol 7 (2):111-122, 1990.	☐
	10	COSTA, J. M. et al., "New strategy for prenatal diagnosis of X-linked disorders." N Engl J Med 346:1502, 2002.	☐
	11	COSTA, J. M. et al., "First-trimester fetal sex determination in maternal serum using real-time PCR." Prenatal Diagn 21:1070-1074, 2001.	☐
	12	DALY, M. J. et al., "High-resolution haplotype structure in the human genome." Nat Genet 29:229-232, 2001.	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10575119
	Filing Date	2006-05-16
	First Named Inventor	Charles Cantor
	Art Unit	1634
	Examiner Name	Misook YU
	Attorney Docket Number	701586-054202

	13	DING and CANTOR, "Direct molecular haplotyping of long-range genomic DNA with M1-PCR " PNAS 100 (13):7449-7453, 2003.	☐
	14	DORIS et al., "Quantitative analysis of gene expression by ion-pair high-performance liquid chromatography." J Chromatography A 806(1):47-60, 1998.	☐
	15	DOUGLAS, J. A. et al., "Experimentally-derived haplotypes substantially increase the efficiency of linkage disequilibrium studies." Nat Genet 28:361-364, 2001.	☐
	16	DRYSDALE et al., "Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness." PNAS 97(19):104483-10488, 2000.	☐
	17	ELSO et al., "Mutation Detection Using Mass Spectrometric Separation of Tiny Oligonucleotide Fragments." Genome Research 12:1428-1433, 2002.	☐
	18	FINNING, K. M. et al., "Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service." Transfusion 42:1079-1085, 2002.	☐
	19	FUCHAROEN, G. et al., "Prenatal detection of fetal hemoglobin E gene from maternal plasma." Prenatal Diagn. 23:393-396, 2003.	☐
	20	FURLONG, R. A. et al., "Analysis of four microsatellite markers on the long arm of chromosome 9 by meiotic recombination in flow-sorted single sperm." Am J Hum Genet 52(6):1191-1199, 1993.	☐
	21	GABRIEL, S. B. et al., "The structure of haplotype blocks in the human genome." Science 296:2225-2229, 2002.	☐
	22	González-González M. C. et al., "Early Huntington disease prenatal diagnosis by maternal semiquantitative fluorescent-PCR." Neurology 60:1214-1215, 2003.	☐
	23	González-González M. C. et al., "Prenatal detection of a cystic fibrosis mutation in fetal DNA from maternal plasma." Prenatal Diagn 22(10):946-948, 2002.	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10575119
	Filing Date	2006-05-16
	First Named Inventor	Charles Cantor
	Art Unit	1634
	Examiner Name	Misook YU
	Attorney Docket Number	701586-054202

	24	HEID et al., "Real time quantitative PCR." Genome Res 6(10):986-994, 1996.	☐
	25	HODGE et al., "Loss of information due to ambiguous haplotyping of SNPs." Nature Genet 21(4).360-361, 1999.	☐
	26	JACQUY et al., "A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin's lymphoma: one-half of patients significantly mobilize malignant cells." Br J Haematology 110(3):631-637, 2000.	☐
	27	JEFFREYS et al., "Amplification of human minisatellites by the polymerase chain reaction: towards DNA fingerprinting of single cells." Nucleic Acids Res 16(23):10953-10971, 1988.	☐
	28	JEFFREYS et al., "Repeat unit sequence variation in minisatellites: a novel source of DNA polymorphism for studying variation and mutation by single molecule analysis." Cell 60(3):473-485, 1990.	☐
	29	JUDSON, R. et al., "The predictive power of haplotypes in clinical response." Pharmacogenomics 1(1):15-26, 2000.	☐
	30	KREBS et al., "Genotyping of dinucleotide tandem repeats by MALDI mass spectrometry of ribozyme-cleaved RNA transcripts." Nature Biotechnology 19:877-880, 2001.	☐
	31	LO, Y. M. et al., "Quantitative analysis of fetal DNA in maternal plasma and serum: implications for noninvasive prenatal diagnosis." Am J Hum Genet 62:768-775, 1998.	☐
	32	LO, Y. M. et al., "Presence of fetal DNA in maternal plasma and serum." Lancet 350(9076):485-487, 1997.	☐
	33	LO, Y. M. Dennis et al., "Prenatal diagnosis of fetal RhD status by molecular analysis of maternal plasma." N Engl J Med 339 1734-1738, 1998.	☐
	34	LO, Y. M., "Detection of minority nucleic acid populations by PCR." J Pathol 174:1-6, 1994.	☐

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)		
	Application Number	10575119
	Filing Date	2006-05-16
	First Named Inventor	Charles Cantor
	Art Unit	1634
	Examiner Name	Misook YU
	Attorney Docket Number	701586-054202

	35	NASIS, O. et al "Improvement in sensitivity of allele-specific PCR facilitates reliable noninvasive prenatal detection of cystic fibrosis." Clin Chem 50 694-701, 2004.	☐
	36	RIJNDERS, R. J. et al., "Clinical applications of cell-free fetal DNA from maternal plasma " Obstet Gynecol 103:157-164, 2004.	☐
	37	SEKIZAWA, A. et al., "Accuracy of fetal gender determination by analysis of DNA in maternal plasma." Clin Chem 47 (10):1856-1858, 2001.	☐
	38	Suomalainen, A. and Syvänen, A. C., "Quantitative analysis of human DNA sequences by PCR and solid-phase minisequencing." Mol Biotechnol 15(2):123-131, 2000.	☐
	39	TANG, et al., "Single nucleotide polymorphism analyses by MALDI-TOF MS." International Journal of Mass Spectrometry 226:37-54, 2003.	☐

If you wish to add additional non-patent literature document citation information please click the Add button Add

EXAMINER SIGNATURE

Examiner Signature		Date Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

[1] See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. [2] Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). [3] For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. [4] Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. [5] Applicant is to place a check mark here if English language translation is attached.